| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.7326/0003-4819-141-8-200410190-00009 |
| P698 | PubMed publication ID | 15492341 |
| P50 | author | Jos Kleijnen | Q28037365 |
| Lizzy M Brewster | Q46207541 | ||
| P2093 | author name string | Gert A van Montfrans | |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 614-627 | |
| P577 | publication date | 2004-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Systematic review: antihypertensive drug therapy in black patients | |
| P478 | volume | 141 |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q37192911 | A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non-White Patients with Hypertension |
| Q30791929 | A case study of a retracted systematic review on interactive health communication applications: impact on media, scientists, and patients |
| Q37247465 | A hypothesis on the origin and evolution of the response to inhaled anesthetics |
| Q59136772 | A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers i |
| Q39148910 | Ambiguities in the Guidelines for the Management of Arterial Hypertension: Indian Perspective with a Call for Global Harmonization. |
| Q33772773 | Anti-hypertensive drugs in children and adolescents |
| Q36938862 | Antihypertensive and Metabolic Effects of Angiotensin Receptor Blocker/Diuretic Combination Therapy in Obese, Hypertensive African American and White Patients |
| Q51744080 | Antihypertensive drug therapy in patients with African ancestry. |
| Q36295517 | Are racial differences in antihypertensive responsiveness reflected in usage after stroke? |
| Q89676252 | Association of West African ancestry and blood pressure control among African Americans taking antihypertensive medication in the Jackson Heart Study |
| Q39497189 | BP Control and Long-Term Risk of ESRD and Mortality |
| Q36331010 | Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment |
| Q46917382 | Calcium channel blocker therapy in black hypertensive patients |
| Q36109561 | Calcium channel blockers: a more expansive treatment role |
| Q46051449 | Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care |
| Q58752251 | Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study |
| Q58804822 | Creatine kinase, energy reserve, and hypertension: from bench to bedside |
| Q33686761 | Development and analyses of evaluation criteria for meta-analysis-relationship between renin-angiotensin system inhibitor and diabetes mellitus |
| Q34220023 | Differences in hypertension between blacks and whites: an overview. |
| Q43119239 | Do black patients with chronic kidney disease benefit equally from all blood pressure lowering agents? |
| Q46880489 | Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial |
| Q64243630 | Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: A meta-analysis and systematic review |
| Q44640623 | Efficacy of Initiating Therapy with Amlodipine and Hydrochlorothiazide or Their Combination in Hypertensive Nigerians |
| Q42931693 | Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial |
| Q37276490 | Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics |
| Q38000015 | Ethnic differences in genetic predisposition to hypertension |
| Q43050632 | Ethnic differences in resistance artery contractility of normotensive pregnant women. |
| Q36736169 | Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management |
| Q45058875 | Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension |
| Q36230385 | Genetic Loci and Novel Discrimination Measures Associated with Blood Pressure Variation in African Americans Living in Tallahassee |
| Q28259560 | Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population |
| Q91593951 | Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans |
| Q36696625 | Genomics in CKD: Is This the Path Forward? |
| Q37959151 | Hypertension and Antihypertensive Therapy in Hispanics and Mexican Americans Living in the United States |
| Q47635539 | Hypertension in African Americans |
| Q37902761 | Hypertension in diverse populations: a New York State Medicaid clinical guidance document |
| Q50990652 | Hypertension management in an outpatient clinic at the Institute of Cardiology of Abidjan (Ivory Coast) |
| Q45166564 | Importance of the Hispanic heritage regarding diagnosis and management of hypertension |
| Q28290776 | Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9 |
| Q36733197 | Maternal ethnicity and its impact on the haemodynamic and blood pressure response to labetalol for the treatment of antenatal hypertension. |
| Q44676500 | Nebivolol/Hydrochlorothiazide : a new fixed-dose combination for effective simplified antihypertensive therapy |
| Q91470316 | Non-Communicable Diseases on the Rise in Sub-Saharan Africa, the Underappreciated Threat of a Dual Disease Burden |
| Q37693131 | Optimizing hypertension management in underserved rural populations |
| Q37147728 | Pediatric hypertension: recent trends and accomplishments, future challenges |
| Q44055125 | Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients. |
| Q90683469 | Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis |
| Q38859866 | Phase 4 Studies in Heart Failure - What is Done and What is Needed? |
| Q46842382 | Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension |
| Q51339073 | Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension |
| Q57033406 | Race-Specific Patterns of Treatment Intensification Among Hypertensive Patients Using Home Blood Pressure Monitoring: Analysis Using Defined Daily Doses in the Heart Healthy Lenoir Study |
| Q37038295 | Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis |
| Q37508558 | Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. |
| Q36811439 | Reaction to Ilesanmi O S et al. The managed hypertensive: the costs of blood pressure control in a Nigerian town |
| Q38886035 | Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis. |
| Q47202999 | Self-assessment of cultural attitudes and competence of clinical investigators to enhance recruitment and participation of minority populations in research |
| Q44442752 | Should African Americans Have a Lower Blood Pressure Goal than Other Ethnic Groups to Prevent Organ Damage? |
| Q35938205 | Stroke in Malawi – What do we know about it and how should we manage it? |
| Q89954971 | Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana |
| Q26749491 | Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity |
| Q33664144 | The Pharmacogenomics of Anti-Hypertensive Therapy |
| Q35170162 | The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC Trial): study protocol for a randomized controlled trial |
| Q36203152 | The impact of race on response to RAAS inhibition |
| Q37858999 | Therapy of Hypertension in African Americans |
| Q36237553 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension |
| Q30248727 | Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement |
| Q38016527 | Update on the Pharmacologic Treatment of Hypertension in Pediatrics |
| Q79219460 | Update on the management of hypertension to prevent stroke |
| Q58820704 | What role does African ancestry play in how hypertensive patients respond to certain antihypertensive drug therapy? |
| Q34747512 | Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review |
Search more.